Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
Editor’s note: This is a developing news story. Please check back soon for updates.
A dual VEGF-A and angiopoietin-2 inhibitor provided fast, durable treatment for wet age-related macular degeneration in a phase 2a study, according to a press release from NovaBridge.
NovaBridge and subsidiary Visara announced topline results from the phase 2a study of VIS-101 for the treatment of wet AMD. VIS-101 is a dual VEGF-A and ANG-2 inhibitor designed to provide more binding sites and increase VEGF-A and ANG-2 affinity, according to the release.
In the study, 38 patients in China with wet AMD were